Loading
Mesothelin is a surface protein on mesothelioma, ovarian, and pancreatic cancers, targeted by ADCs, CAR-T, and T-cell engagers. This dossier gathers the 2 products (0 approved), 9 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Binds MUC16/CA-125; function largely dispensable.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Mesothelioma | 85-100% | Epithelioid histology | Lower in sarcomatoid | Wikipedia |
| Pancreatic ductal adenocarcinoma | 80-90% | IHC, any expression | Wikipedia | |
| Ovarian cancer | 60-70% | IHC, any expression | Serous | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Phase 2 | Withdrawn or failed |
|---|---|---|
| ADC 1 | - | |
| Bispecific antibody 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 2 | Negative | Second-line, unresectable locally advanced or metastatic malignant pleural mesothelioma over-expressing mesothelin after platinum and pemetrexed, randomised open-label at 76 hospitals in 14 countries | PFS 4.3 vs 4.5 months, HR 1.22; primary endpoint not met. | ||
ECLIPSE (GVAX pancreas and CRS-207) NCT02004262 | 2 | Negative | Previously treated metastatic pancreatic adenocarcinoma in the United States and Canada: cyclophosphamide with GVAX pancreas then CRS-207 (live attenuated Listeria expressing mesothelin), CRS-207 alone, or single-agent chemotherapy, randomised 1 to 1 to 1, with overall survival in patients after two or more prior lines as the primary endpoint | Median overall survival 3.7 months with cyclophosphamide, GVAX pancreas and CRS-207 against 4.6 months with chemotherapy in the primary cohort (hazard ratio 1.17, 95 percent confidence interval 0.84 to 1.64); CRS-207 alone 5.4 months. | |
| 1/2 | Active | Previously treated mesothelin-positive pleural mesothelioma; phase 1 safety run-in then randomisation between pembrolizumab alone and pembrolizumab with anetumab ravtansine, started October 2018 | - | ||
| 1/2 | Recruiting | A Multicenter, Open-label Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of HY05350 for Injection in Patients With MSLN-positive Advanced Solid Tumors | - | - | |
| 1/2 | Recruiting | A Phase 1/2, Open-label, Biomarker-guided Study of Dual-target Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Targeting Mesothelin (MSLN) With EGFR or HER2/ERBB2, or EGFR With HER2/ERBB2, in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) | - | - | |
| 1/2 | Recruiting | A Phase 1/2, Open-label, Biomarker-guided Study of Dual-target Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Targeting Mesothelin (MSLN) With EGFR or HER2/ERBB2, or EGFR With HER2/ERBB2, in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) | - | - | |
| 1/2 | Recruiting | A Phase 1/2, Open-Label, Nonrandomized, Biomarker-Guided Study of Locoregional Allogeneic Dual-Target Mesothelin (MSLN) / Fibroblast Activation Protein (FAP) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Recurrent, or Refractory Pleural or Peritoneal Mesothelioma | - | ||
| 1/2 | Recruiting | A Phase 1/2, Open-Label, Biomarker-Assigned Study of Dual-Targeting CAR-NK Cells Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα/FOLR1), and/or MUC16 (CA125) in Patients With Recurrent or Refractory High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | - | - | |
| 1/2 | Recruiting | Dual-Target Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Mesothelin" OR ABSTRACT:"Mesothelin" OR TITLE:"MSLN" OR ABSTRACT:"MSLN") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mesothelin, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/mesothelin.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/mesothelin.json. Licence CC BY-NC 4.0.